Fluocortolone caproate

Identification

Summary

Fluocortolone caproate is a corticosteroid indicated in the treatment of hemorrhoids, anal fissures, and corticosteroid-responsive dermatoses.

Generic Name

Fluocortolone caproate

DrugBank Accession Number

DB15821

Background

Not Available

Type

Small Molecule

Groups

Experimental

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Fluocortolone caproate (DB15821)

×

Close

Weight

Average: 474.613
Monoisotopic: 474.278152519

Chemical Formula

C₂₈H₃₉FO₅

Synonyms

• Fluocortolone 21-caproate
• Fluocortolone 21-hexanoate
• Fluocortolone caproate
• Fluocortolone hexanoate

External IDs

• SH 770
• SH-770

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Used in combination to treat	Anal fissures	Combination Product in combination with: Fluocortolone pivalate (DB15777), Cinchocaine (DB00527)	••••••••••••	•••••		••••••••• •••••••••••
Used in combination to treat	Hemorrhoids	Combination Product in combination with: Cinchocaine (DB00527), Fluocortolone pivalate (DB15777)	••••••••••••	•••••		••••••••• •••••••••••
Used in combination to treat	Proctitis	Combination Product in combination with: Fluocortolone pivalate (DB15777), Cinchocaine (DB00527)	••••••••••••	•••••		••••••••• •••••••••••
Used in combination to treat	Corticosteroid-responsive dermatosis	Combination Product in combination with: Fluocortolone pivalate (DB15777)	••••••••••••			•••••• ••••••••
Used in combination to treat	Corticosteroid-responsive dermatosis	Combination Product in combination with: Fluocortolone pivalate (DB15777)	••••••••••••			•••••• ••••••••

Create Account

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Acarbose	The risk or severity of hyperglycemia can be increased when Fluocortolone caproate is combined with Acarbose.
Aceclofenac	The risk or severity of gastrointestinal irritation can be increased when Fluocortolone caproate is combined with Aceclofenac.
Acemetacin	The risk or severity of gastrointestinal irritation can be increased when Fluocortolone caproate is combined with Acemetacin.
Acenocoumarol	Fluocortolone caproate may increase the anticoagulant activities of Acenocoumarol.
Acetohexamide	The risk or severity of hyperglycemia can be increased when Fluocortolone caproate is combined with Acetohexamide.

Food Interactions

Not Available

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

International/Other Brands

Ficoid / Ultralanum

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
ULTRALAN DERMATOLOGICO	Fluocortolone caproate (0.25 %) + Fluocortolone pivalate (0.25 %)	Cream	Topical	Karo Pharma Ab	2014-07-08	2021-08-11
ULTRALAN DERMATOLOGICO	Fluocortolone caproate (0.25 %) + Fluocortolone pivalate (0.25 %)	Ointment	Topical	Karo Pharma Ab	2014-07-08	2020-09-25
ULTRALAN DERMATOLOGICO	Fluocortolone caproate (0.25 %) + Fluocortolone pivalate (0.25 %)	Cream	Topical	Karo Pharma Ab	2014-07-08	Not applicable
ULTRALAN DERMATOLOGICO	Fluocortolone caproate (0.25 %) + Fluocortolone pivalate (0.25 %)	Ointment	Topical	Karo Pharma Ab	2014-07-08	2020-09-25
ULTRALAN DERMATOLOGICO	Fluocortolone caproate (0.25 %) + Fluocortolone pivalate (0.25 %)	Ointment	Topical	Karo Pharma Ab	2014-07-08	2023-03-05

Categories

Drug Categories

• Adrenal Cortex Hormones
• Anti-Inflammatory Agents
• Corticosteroids
• Fused-Ring Compounds
• Glucocorticoids
• Hormones
• Hormones, Hormone Substitutes, and Hormone Antagonists
• Pregnadienediols
• Pregnadienes
• Pregnanes
• Steroids
• Steroids, Fluorinated

Classification

Not classified

Affected organisms

Not Available

Chemical Identifiers

UNII

90893P8662

CAS number

303-40-2

InChI Key

WHZRCUIISKRTJL-YTZKRAOUSA-N

InChI

InChI=1S/C28H39FO5/c1-5-6-7-8-24(33)34-15-23(32)25-16(2)11-19-18-13-21(29)20-12-17(30)9-10-27(20,3)26(18)22(31)14-28(19,25)4/h9-10,12,16,18-19,21-22,25-26,31H,5-8,11,13-15H2,1-4H3/t16-,18+,19+,21+,22+,25-,26-,27+,28+/m1/s1

IUPAC Name

2-[(1S,2R,3aS,3bS,5S,9aR,9bS,10S,11aS)-5-fluoro-10-hydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl hexanoate

SMILES

[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)CCCCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C

References

General References

1. AIFA: Ultralan (Fluocortolone) Topical Cream [Link]
2. TITCK Product Information: ULTRAPROCT (cinchocaine, fluocortolone pivalate, and fluocortolone caproate) rectal [Link]

External Links

ChemSpider

16735815

RxNav

4464

ChEMBL

CHEMBL2107415

ZINC

ZINC000004213356

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Cream	Topical
Emulsion	Topical
Lotion	Topical
Ointment	Topical
Ointment	Rectal
Suppository	Rectal

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0017 mg/mL	ALOGPS
logP	3.67	ALOGPS
logP	4.44	Chemaxon
logS	-5.4	ALOGPS
pKa (Strongest Acidic)	15.15	Chemaxon
pKa (Strongest Basic)	-0.23	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	4	Chemaxon
Hydrogen Donor Count	1	Chemaxon
Polar Surface Area	80.67 Å2	Chemaxon
Rotatable Bond Count	8	Chemaxon
Refractivity	129.05 m3·mol-1	Chemaxon
Polarizability	52.93 Å3	Chemaxon
Number of Rings	4	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	Yes	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0a6r-3009500000-3ba44af03b6cff4a342f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-00r2-9304400000-bf850a3c48d0361840ea
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-002b-9007100000-f3cbb0be977d3d2e4fac
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0a6r-3009400000-38d269795c540cfdb713
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0a6u-9000000000-570e6b2fac75da65f585
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-00o0-9225000000-0b126925daf8858c4f50
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Not Available

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at September 09, 2020 20:13 / Updated at May 14, 2021 01:08